

Suppl Table 7. Demographic data for patients with adrenocortical carcinoma in the adjuvant mitotane cohort (n=795)

Variable	No mitotane adjuvant	Mitotane adjuvant	P value
N	314	481	-
Age, years	51 (39, 61)	49 (38, 60)	0.0824
Male, n(%)	131 (41.7)	175 (36.4)	0.131
Symptoms at diagnosis, n(%)	198 (63.1)	338 (70.3)	0.034
Symptom type, n(%)			
None	116 (36.9)	143 (29.7)	0.257
Tumour mass	57 (18.2)	88 (18.3)	
Steroids	114 (36.3)	198 (41.2)	
Cancer-related	10 (3.2)	22 (4.6)	
Combinations of the above	17 (5.4)	30 (6.2)	
Hormone pattern, n(%)			
Non-functional	131 (41.7)	192 (39.9)	0.739
Glucocorticoid excess	59 (18.8)	101 (21.0)	
Androgen excess	26 (8.3)	40 (8.3)	
Combinations of the above or other	69 (21.9)	114 (23.7)	
Unknown	29 (9.2)	34 (7.1)	
ENSAT tumour stage at diagnosis, n(%)			
1	47 (15.0)	38 (8.0)	0.017
2	172 (54.8)	291 (60.5)	
3	80 (25.5)	130 (27.0)	
4	15 (4.8)	22 (4.6)	
Ki67 index	10 (5, 20)	18 (10, 30)	
Ki67 index (categories), n(%)			
0-9	141 (44.9)	112 (23.3)	< 0.0001
10-19	68 (21.7)	130 (27.0)	
≥20	105 (33.4)	239 (49.7)	
Resection status of primary tumour, n(%)			
R0	260 (82.8)	379 (78.8)	0.357
RX	36 (11.5)	65 (13.5)	
R1	18 (5.73)	37 (7.7)	
S-GRAS group, n(%)			
0-1	98 (31.21)	68 (14.1)	< 0.0001
2-3	122 (38.9)	238 (49.5)	
4-5	76 (24.2)	144 (29.94)	
6-9	18 (5.7)	31 (6.4)	
Disease recurrence, progress or death*, n(%)	176 (56.1)	267 (55.5)	0.881
Disease-specific death, n(%)	80 (25.5)	112 (23.3)	0.480
Death of any cause, n(%)	83 (26.4)	121 (25.2)	0.687
Continuous variables presented as median (and interquartile range).*disease-related death.			